3.1. epidemiology. urothelial carcinoma (uc) second common urological malignancy developed countries . localised lower (bladder urethra) and/or upper (pyelocaliceal cavities ureter) urinary tract. bladder cancer (bc) accounts 90–95% ucs whilst upper tract urothelial carcinomas (utuc) account 5–10% ucs estimated annual incidence western countries almost two cases per 100,000 inhabitants . rate risen past decades likely result improved detection aging population . peak incidence individuals aged 70–90 years utuc twice common men . retrospective international registry including data 2,380 patients diagnosed 2014 2019 (101 centres 29 countries) confirmed utuc patients predominantly male (70.5%) 53.3% past present smokers. majority patients (53%) diagnosed presented symptoms, mainly visible haematuria . confirmed meta-analysis pooling 44 studies showed pooled utuc incidence rate 0.75% patients visible haematuria 0.17% non-visible haematuria . addition, approximately two-thirds patients present utucs muscle-invasive disease diagnosis compared 15–25% patients diagnosed de novo bc . higher incidence muscle-invasive disease utuc vs. bc confirmed population-based studies germany england suggesting muscle-invasive utuc represents approximately half incident cases recent years . approximately 9% patients present metastasis [8,16-18]. pyelocaliceal tumours approximately twice common ureteral tumours multifocal tumours found approximately 10–20% cases . presence concomitant carcinoma situ upper tract 11% 36% . 17% cases, concurrent bc present whilst prior history bc found 41% american men 4% chinese men . this, along genetic epigenetic factors, may explain asian patients present advanced higher-grade disease compared ethnic groups . following treatment, recurrence bladder occurs 29% utuc patients, depending patient-, tumour- treatment-specific characteristics compared 2–5% recurrence rate contralateral upper tract . upper tract uc bc exhibit significant differences prevalence common genomic alterations. individual patients history tumours, bc utuc often clonally related. genomic characterisation utuc provides information regarding risk bladder recurrence identify tumours associated lynch syndrome . regarding utuc occurring patients bc, 82 patients treated intravesical bacillus calmette-guérin (bcg) high-risk bc regular upper tract imaging years 1 3, 13% developed utuc, asymptomatic , whilst another series 307 patients without routine upper tract imaging incidence utuc bc 25% . multicentre cohort study (n = 402) 50 month follow-up demonstrated utuc incidence 7.5% nmibc patients receiving bcg predictors intravesical recurrence non-papillary tumour transurethral resection bladder (turb) . following radical cystectomy mibc, 3–5% patients develop metachronous utuc .